Question explored with the scientific record
Conversation so far
- 1 Atorvastatin for 73 year old. Been on statins for 30 years. + a private exchange
- 2 Atorvastatin for 73 year old. Been on statins for 30 years. Also on BP tablets, at the time no heart issues, so preventative
Answered on this page ↓
Atorvastatin for 73 year old. Been on statins for 30 years. Also on BP tablets, at the time no heart issues, so preventative
The short version: for a 73-year-old with no heart disease, the statin benefit is real but modest, and the muscle risk is the part the schedule never mentions.
The primary-prevention numbers are the ones that matter here, and they shrink with age. Rosuvastatin cut major heart events by 49% in people 65 to 70, but only 26% in people over 70 [1]. In people over 70 with no heart disease, the drop in total deaths was not statistically significant [1]. That is the honest size of the benefit: fewer heart attacks and strokes, not clearly fewer deaths.
The muscle side is underplayed. In one large unselected group on statins, about 10 in 100 reported muscle symptoms [5]. In a French cohort, 10.5% had muscle-related symptoms over a year [3]. Risk climbs with age, female sex, kidney problems, and high dose [2][3]. Low vitamin D and a gene variant each roughly quadrupled myopathy risk in one Swedish cohort [4]. Atorvastatin carries less of the gene-linked risk than simvastatin [3].
| Group | Outcome | Result |
|---|---|---|
| 65 to 70, no heart disease | Major heart events | 49% relative cut [1] |
| Over 70, no heart disease | Major heart events | 26% relative cut [1] |
| Over 70, no heart disease | Total deaths | Not significant [1] |
| Statin users, unselected | Muscle symptoms | About 10 in 100 [5] |
| Statin users | Rhabdomyolysis (severe muscle breakdown) | 0.01% [1] |
What is missing: no trial here compares 30-year users to people who stopped, and none tests statin plus a specific blood-pressure drug at 73. Those are the studies that would settle the long-term question.
My call: continuing is defensible if there are no muscle symptoms, but the dose should be the lowest that holds LDL at goal, and any new muscle pain should be taken seriously, not dismissed. Confidence: moderate.
Sources used 5
-
Should statin therapy be used in medication of elderly patients?
The author concludes that statin therapy is useful in elderly patients, with mandatory use in secondary prevention and lower, individually adjusted doses in primary prevention, while excluding patients with terminal illness, frailty, or dialysis.
DOI: 10.5937/galmed2202065d -
Risk of myopathy with statin and fibrate treatment
This Drug Points case describes an 81-year-old woman with type 2 diabetes, renal impairment and high-dose atorvastatin in whom a fibrate was requested, illustrating why prescribers should individualize guideline recommendations because of statin-associated myopathy risk.
DOI: 10.1002/psb.58 -
Narrative Review: Statin-Related Myopathy
This narrative review synthesizes current knowledge on statin-related myopathy, detailing definitions, mechanisms, epidemiology, clinical features, risk factors, management strategies, and emerging pharmacogenetic and adjunctive treatment data.
DOI: 10.7326/0003-4819-150-12-200906160-00009 -
Low Vitamin D Levels and Genetic Polymorphism in the Vitamin D Receptor are Associated with Increased Risk of Statin‐Induced Myopathy
A Swedish prospective observational study found that baseline low 25-hydroxyvitamin D (<50 nmol/L) and a vitamin D receptor TaqI CC genotype are associated with markedly increased risk of statin-induced myopathy within one year, suggesting vitamin D status and VDR genetics may p…
DOI: 10.1111/bcpt.12482 -
Statin-associated myopathy: a general overview
This narrative review summarizes statin-associated myopathy, its clinical spectrum, proposed mechanisms, risk factors, and management, citing prior observational and interventional studies.
DOI: 10.18621/eurj.416772